> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Atea Says $200 Million In Debt Could Cover Its Drug Launch Without Selling Shares
- URL: https://www.bullished.co/atea-says-200-million-in-debt-could-cover-its-drug-launch-without-selling-shares-9cb49fdf/
- Published: 2026-11-09T22:25:53.000Z
- Updated: 2026-11-09T22:25:53.000Z
- Description: Atea received $65 million at closing, while access to another $135 million depends on milestones and other conditions.
- Author: Matteo Parrino
- Tags: Earnings, AVIR, Industry: Healthcare

[Atea Pharmaceuticals](https://www.bullished.co/tag/avir/), which develops oral antiviral drugs, could finance its anticipated U.S. hepatitis C launch without selling shares, Andrea Corcoran said Monday on the company's earnings call. She said the up-to-$200 million credit facility would cover commercialization under Atea's operating plan, though most of the borrowing remains conditional.

## $65 Million Now, More On Conditions

Asked whether Atea would need to tap the equity market to launch, Corcoran said the full facility would be "more than sufficient to get us through the commercial launch." She added that it "would alleviate the need for any equity financing."

Atea received $65 million from Hercules Capital when the financing closed Friday. Corcoran expects that money and existing resources to pay for planned operations into mid-2028\. Atea can choose to borrow up to another $135 million, subject to specified milestones and other conditions.

The distinction matters for shareholders: management's assessment that it can avoid issuing shares rests on the full facility, rather than just the money already received. Corcoran said the financing could carry Atea through profitability if its U.S. launch succeeds and future spending follows its current operating plans.

Cash and investments were [$191.2 million](https://seekingalpha.com/news/4669339-atea-pharmaceuticals-gaap-eps-of-0%5F40-beats-by-0%5F02?ref=bullished.co) at September 30, down from $301.8 million at December 31, 2025\. Third-quarter spending mainly supported the late-stage hepatitis C trials, with a smaller portion going toward starting the hepatitis E trial.

## An Eight-Week Regimen Nears Its Test

Atea has no drugs approved for sale. Its hepatitis C candidate combines bemnifosbuvir and ruzasvir; its other program, AT-587, targets chronic hepatitis E in immunocompromised patients. The company [targets a launch](https://www.globenewswire.com/news-release/2026/11/09/3398239/0/en/atea-pharmaceuticals-secures-credit-facility-for-up-to-200-million-from-hercules-capital.html?ref=bullished.co) of the hepatitis C regimen in 2028 if approved.

Positive results from the North American late-stage trial, C-BEYOND, were announced in July. Arantxa Horga, Atea's chief medical officer, said the regimen achieved a 94% cure rate against 95% for sofosbuvir and velpatasvir, meeting the trial's main goal of showing comparable efficacy within a preset margin.

Patients without cirrhosis took Atea's regimen for eight weeks, versus 12 weeks for the comparator. Patients with compensated cirrhosis received 12 weeks of either treatment; both groups achieved 95% cure rates. Horga said adverse events were comparable and no serious adverse events were attributed to the study drugs.

Jean-Pierre Sommadossi, Atea's chief executive officer and founder, expects results from C-FORWARD, the global trial spanning 17 countries, early in 2027\. If those data are positive, Atea targets an FDA approval application for mid-2027.

## The Launch Bet Extends Beyond Trials

John Vavricka, Atea's chief commercial officer, put potential peak annual U.S. sales above $700 million. He argued that the commercial opportunity extends beyond switching patients from existing drugs: only around half of patients diagnosed in 2025 were treated, leaving roughly 75,000 newly diagnosed infections untreated.

U.S. hepatitis C drug sales totaled $1.3 billion in 2025, out of approximately $2.6 billion globally. Vavricka said Atea expects pricing in line with existing branded antiviral regimens and is preparing manufacturing and launch supplies. He said Medicaid covers roughly half of the current U.S. market, with Medicare and commercial coverage accounting for the rest.

The financing also supports AT-587\. Janet Hammond, Atea's chief development officer, said its early-stage study in healthy volunteers has completed single-dose testing and is progressing through multiple-dose testing. Management expects those results early in 2027 and plans a proof-of-concept study in infected patients in the first half of 2027, with preliminary results anticipated late that year.

For the hepatitis C launch, the next clinical checkpoint is C-FORWARD's expected early-2027 readout; access to the remaining financing still depends on milestones and other conditions.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Atea Pharmaceuticals Q3 2026 Earnings Preview (AVIR:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4668190-atea-pharmaceuticals-q3-2026-earnings-preview?ref=bullished.co) — seekingalpha.com
- [Atea Pharmaceuticals GAAP EPS of -$0.40 beats by $0.02 (AVIR:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4669339-atea-pharmaceuticals-gaap-eps-of-0%5F40-beats-by-0%5F02?ref=bullished.co) — seekingalpha.com
- [Atea Pharmaceuticals Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/09/3398942/0/en/atea-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com
- [Atea Pharmaceuticals Secures Credit Facility for Up to $200](https://www.globenewswire.com/news-release/2026/11/09/3398239/0/en/atea-pharmaceuticals-secures-credit-facility-for-up-to-200-million-from-hercules-capital.html?ref=bullished.co) — globenewswire.com

### More on Atea Pharmaceuticals

- [Atea Narrows Loss To $32.2 Million As Hepatitis C Trial Costs Fall](https://www.bullished.co/atea-narrows-loss-to-32-2-million-as-hepatitis-c-trial-costs-fall-ee4e209e/)
- [Atea Pharmaceuticals Borrows $65 Million As Further Loans Hinge On Hepatitis C Milestones](https://www.bullished.co/atea-pharmaceuticals-borrows-65-million-as-further-loans-hinge-on-hepatitis-c-milestones-49e2ae2f/)
- [Tang Capital Reports 4.8 Million Atea Shares, A 6% Passive Stake, In SEC Filing](https://www.bullished.co/tang-capital-reports-4-8-million-atea-shares-a-6-passive-stake-in-sec-filing-f831354a/)

[All Atea Pharmaceuticals (AVIR) coverage →](https://www.bullished.co/tag/avir/)